文献速递垂体与肾上腺疾病

免疫检查点抑制剂治疗侵袭性垂体神经内分泌肿瘤

Immune Checkpoint Inhibitor Therapy for Aggressive Pituitary Neuroendocrine Tumors.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

单中心前瞻性2期试验评估伊匹木单抗联合纳武利尤单抗治疗垂体神经内分泌肿瘤的活性,主要终点采用iRANO标准,10例入组、9例可评估,未观察到客观缓解但2/9例肿瘤缩小;生物标志物队列发现替莫唑胺超突变和错配修复缺陷与免疫应答相关。

要点

  • 伊匹木单抗联合纳武利尤单抗治疗侵袭性垂体神经内分泌肿瘤安全可行。
  • 9例可评估患者中无客观缓解,但2例出现肿瘤缩小。
  • 替莫唑胺超突变和错配修复缺陷与免疫应答相关。

核心结论

  • 本研究证明免疫检查点抑制剂治疗侵袭性垂体神经内分泌肿瘤安全可行。
  • 错配修复缺陷和替莫唑胺超突变被确定为免疫检查点抑制剂应答的潜在生物标志物。
  • 数据提示免疫检查点抑制剂可能为垂体神经内分泌肿瘤提供额外治疗选择,应在未来研究中更广泛评估。

研究设计与样本

  • 单中心、前瞻性、2期试验,研究伊匹木单抗和纳武利尤单抗在垂体神经内分泌肿瘤患者中的活性。
  • 主要终点为采用iRANO应答标准的客观缓解。
  • 在13例接受免疫检查点抑制剂治疗(试验内或试验外)的垂体神经内分泌肿瘤患者中探索免疫检查点抑制剂应答的遗传生物标志物。
  • 10例垂体神经内分泌肿瘤患者入组,包括5例促肾上腺皮质激素细胞瘤、4例催乳素细胞瘤和1例生长激素细胞瘤。
  • 10例中9例(4例转移性和5例非转移性)可评估主要终点。

主要发现

  • 未观察到客观缓解,但9例可评估患者中2例出现肿瘤缩小。
  • 生物标志物发现队列包括7例试验内治疗肿瘤和6例试验外治疗肿瘤,替莫唑胺超突变和错配修复缺陷与免疫应答相关。
  • 在3例免疫检查点抑制剂治疗前后测序的肿瘤中,鉴定出免疫编辑证据,特征为错配修复缺陷丢失和/或肿瘤突变负荷降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Pituitary neuroendocrine tumors (PitNETs) that progress following surgery and radiotherapy are in need of additional treatment options. Responses to immune checkpoint inhibitors (ICIs) have been described; however, the feasibility of ICI therapy and biomarkers of response have not been formally assessed. OBJECTIVE: To evaluate the activity of ICI as a treatment for PitNETs. METHODS: We performed a single-center, prospective, phase 2 trial investigating the activity of ipilimumab and nivolumab in patients with PitNETs. The primary endpoint was objective response using the iRANO response criteria. We then explored genetic biomarkers of response to ICIs in 13 patients with PitNETs who were treated with ICIs, on or outside of the trial. RESULTS: Ten patients with a PitNET were enrolled, including 5 corticotroph, 4 lactotroph, and 1 somatotroph tumor, of which 9/10 (4 metastatic and 5 nonmetastatic) patients were evaluable for the primary endpoint. While no objective responses were observed, tumor shrinkage was seen in 2/9 patients. In a biomarker discovery cohort, comprising 7 tumors treated on trial and 6 tumors treated off trial, temozolomide hypermutation, and mismatch repair deficiency (MMRd) were associated with immunological response. In 3 tumors sequenced pre- and post-ICI treatment, we identified evidence of immunoediting, characterized by loss of MMRd and/or a decrease in tumor mutational burden. CONCLUSION: This study demonstrates the safety and feasibility of ICI treatment in aggressive PitNETs. We also identified MMRd and temozolomide hypermutation as potential biomarkers of response to ICI. Overall, our data suggest that ICIs might provide an additional treatment option for PitNET; this should be evaluated more broadly in future studies.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lin AL, Rudneva V, Newton A, et al. Immune Checkpoint Inhibitor Therapy for Aggressive Pituitary Neuroendocrine Tumors. J Clin Endocrinol Metab. 2025. PMID: 40109237. doi:10.1210/clinem/dgaf178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。